Swiss National Bank Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Swiss National Bank acquired a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 67,400 shares of the biotechnology company's stock, valued at approximately $930,000. Swiss National Bank owned about 0.15% of Capricor Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its holdings in Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock worth $1,536,000 after purchasing an additional 37,868 shares during the period. Magnus Financial Group LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth $276,000. State Street Corp lifted its holdings in Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after acquiring an additional 111,291 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Capricor Therapeutics by 419.5% in the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock valued at $855,000 after acquiring an additional 45,381 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of Capricor Therapeutics in the third quarter worth about $3,806,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on CAPR. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR traded up $0.26 during mid-day trading on Wednesday, hitting $9.74. 1,233,160 shares of the company's stock were exchanged, compared to its average volume of 1,425,189. Capricor Therapeutics Inc has a 52 week low of $3.52 and a 52 week high of $23.40. The company has a 50-day simple moving average of $13.72 and a 200 day simple moving average of $15.03. The company has a market cap of $444.88 million, a PE ratio of -9.19 and a beta of 4.09.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. On average, analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.